- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Chinese vaccine manufacturer Walvax Biotechnology has registered for a Phase III clinical study of a new mRNA vaccine ARCoV. This is the first mRNA vaccine to be developed in the country. According to media, 6,000 participants in Mexico will be recruited starting at the end of May. A key difference with this vaccine is that it requires less stringent temperature requirements than the Moderna and Pfizer mRNA vaccines.
Further information on the Pfizer vaccine may be found here.
Further information on the Moderna vaccine may be found here.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
